BRIEF-Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity Treatment

Reuters
24 Apr
BRIEF-Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity Treatment

April 24 (Reuters) - PMGC Holdings Inc ELAB.O:

  • NORTHSTRIVE BIOSCIENCES ANNOUNCES POSITIVE FDA RESPONSE SUPPORTING A SUBMISSION OF IND FOR A PHASE 2 CLINICAL TRIAL FOR EL-22 IN COMBINATION WITH GLP-1 RECEPTOR AGONIST FOR OBESITY TREATMENT

  • PMGC HOLDINGS INC - NORTHSTRIVE TO FILE IND APPLICATION IN 2025

Source text: ID:nGNX63yVMb

Further company coverage: ELAB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10